Table 5 Anemia parameters and the use of ESA and iron
Characteristics | Total (n = 1129) | CKD Stage 3 (n= 434) | CKD Stage 4 (n= 695) | Pvalue |
|---|---|---|---|---|
Anemia according to K-DOQI guidelines (%) | 51.3 | 43.7 | 58.1 | 0.001 |
Anemia according to EBPG (%) | 30.5 | 25.5 | 36.0 | 0.001 |
Hemoglobin (g/dL; mean ± SD [range]) | 12.8 ± 1.6 [7.6-18.7] | 13.2 ± 1.7 [7.6-18.7] | 12.4 ± 1.6 [7.6-16.9] | 0.001 |
% of patients with Hemoglobin levels greater than 11 gm/dL | 87.8 | 91.1 | 85.5 | 0.001 |
% of patients with Hemoglobin levels between 9 and 11 gm/dL | 11.5 | 8.6 | 13.3 | 0.095 |
% of patients with Hemoglobin levels less than 9 gm/dL | 1.6 | 0.5 | 2.3 | 0.001 |
Treatment with ESA* (%) | 25.5 | 16.0 | 34.1 | 0.001 |
Mean hemoglobin levels in patients treated with ESA (g/dL; mean ± SD [range]) | 12.0 ± 1.5 [7.0-17.4] | 12.3 ± 1.5 [9.3-17.4] | 12.0 ± 1.5 [7.0-16.2] | 0.15 |
Ferritin (ng/mL; mean ± SD [range]) | 150 ± 47 [5-1500] | 129 ± 117 [5-997] | 169 ± 168 [5-1500] | 0.001 |
Iron (μg/dl; mean ± SD [range]) | 70 ± 26 [6-230] | 75 ± 28 [6-230] | 67 ± 25 [9-197] | 0.001 |
Transferrin saturation < 20% (%) | 26.3 | 23.4 | 28.5 | 0.12 |
Treatment with oral Iron (%) | 31.9 | 23.6 | 39.5 | 0.001 |
Treatment with intravenous Iron (%) | 3.0 | 1.6 | 4.4 | 0.001 |